Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 11, 2023--

Related Keywords

United Kingdom ,Massachusetts ,United States ,Spain ,France ,Germany ,Australia ,Turkey ,Chile ,Poland ,Belgium ,Israel ,Portugal ,Canada ,Greece ,Italy ,Lavina Talukdar ,Peter Dannenbaum ,Luke Mircea Willats ,Kyle Holen ,Damini Chokshi ,Julie Cunningham ,Instagram ,Moderna Inc ,Exchange Commission ,Merck Co Inc ,International Media Relations Communications ,Linkedin ,Twitter ,Nasdaq ,Merck Research Laboratories ,Youtube ,Statement Of Merck Co Inc ,Head Of Development ,Facebook ,Marjorie Green ,Merck Research ,Senior Vice President ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,Neck Squamous Cell ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Private Securities Litigation Reform Act ,Prescribing Information ,Medication Guide ,Merck Media Contacts ,Investor Contacts ,Media Contacts ,International Media Relations ,Vice President ,Business Wire ,National Business ,